In planta produced virus-like particles as candidate vaccines

Plants are promising biotechnological tools for the production of pharmaceutical proteins and vaccines due to their advantages in terms of costs, feasibility and scalability of production. Among biopharmaceuticals, virus-like particles (VLPs) composed of single or multiple virus proteins with self-assembly capacity represent one of the most attractive systems of antigen production in plants. This is due to the potent immunogenic capacity and safety of VLPs which might be used as plant-made vaccines against various human and animal diseases. Furthermore, VLPs do not require long purification steps and the cold chain, which are limiting factors in the production of conventional vaccines. These characteristics allow VLPs to compete as ideal alternative candidate vaccines, either as simple products or as more complex platforms to carry heterologous immunogenic sequences on their surfaces. In this chapter, we report the progress on the production of VLPs of four well-defined human/animal viruses (Papillomaviruses, Hepatitis B virus, Human immunodeficiency virus 1 and Influenza A virus) in plants.

[1]  T. Pniewski.  Is an oral plant-based vaccine against hepatitis B virus possible? , 2012, Current pharmaceutical biotechnology.

[2]  E. Freed,et al.  HIV-1 gag proteins: diverse functions in the virus life cycle. , 1998, Virology.

[3]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[4]  G. Lomonossoff,et al.  pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. , 2009, Plant biotechnology journal.

[5]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[6]  J. Torresi.  The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  P. Krajewski,et al.  Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation , 2012, Plant Cell Reports.

[8]  Zhong Huang,et al.  High‐yield rapid production of hepatitis B surface antigen in plant leaf by a viral expression system , 2008 .

[9]  Dabing Zhang,et al.  Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. , 2005, Viral immunology.

[10]  T. Pniewski,et al.  Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation , 2010, Journal of Applied Genetics.

[11]  E. Rybicki,et al.  High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. , 2010, Plant biotechnology journal.

[12]  L. Laimins,et al.  Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity , 2006, Reviews in medical virology.

[13]  M. Campo.  Vaccination against papillomavirus in cattle. , 1997, Current topics in microbiology and immunology.

[14]  Sarah A Kessans,et al.  Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana , 2013, Plant biotechnology journal.

[15]  S. Harrison,et al.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. , 2000, Molecular cell.

[16]  E. Rybicki,et al.  Expression of HIV-1 antigens in plants as potential subunit vaccines , 2008, BMC biotechnology.

[17]  N. Ravin,et al.  Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein , 2012, Biochemistry (Moscow).

[18]  R. Milne,et al.  Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. , 2012, Plant biotechnology journal.

[19]  O. Kiselev,et al.  Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. , 2013, Current pharmaceutical design.

[20]  R. Rose,et al.  Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi , 2003, Archives of Virology.

[21]  M. L. Mora-García,et al.  An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice , 2009, Virology Journal.

[22]  N. Gitlin.  Hepatitis B: diagnosis, prevention, and treatment. , 1997, Clinical chemistry.

[23]  P. Lyons,et al.  Immunogenicity of transgenic plant-derived hepatitis B surface antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Skryabin,et al.  The use of viral vectors to produce hepatitis B virus core particles in plants. , 2006, Journal of virological methods.

[25]  F. Buonaguro,et al.  High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts , 2009, Planta.

[26]  D. M. Lam,et al.  Expression of hepatitis B surface antigen in transgenic plants. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Aaronson,et al.  Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses , 1985, Nature.

[28]  P. Di Bonito,et al.  Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. , 2006, International journal of immunopathology and pharmacology.

[29]  V. Masenga,et al.  Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants , 2011, BMC biotechnology.

[30]  Brian J Ward,et al.  Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. , 2008, Plant biotechnology journal.

[31]  J. Briggs,et al.  The molecular architecture of HIV. , 2011, Journal of molecular biology.

[32]  L. Nasir,et al.  Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. , 2008, Veterinary dermatology.

[33]  D. Baulcombe,et al.  Potato virus X as a vector for gene expression in plants. , 1992, The Plant journal : for cell and molecular biology.

[34]  S. Hassan,et al.  Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes. , 2011, Plant biotechnology journal.

[35]  Julia R Gog,et al.  Genome packaging in influenza A virus. , 2010, The Journal of general virology.

[36]  S. Chapman,et al.  In planta production of a candidate vaccine against bovine papillomavirus type 1 , 2012, Planta.

[37]  F. Buonaguro,et al.  Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco , 2008, Transgenic Research.

[38]  F. Kostolanský,et al.  HA2 glycopolypeptide of influenza A virus and antiviral immunity. , 2013, Acta virologica.

[39]  E. Rybicki,et al.  Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. , 2013, Plant biotechnology journal.

[40]  Q. Yao,et al.  Virus‐like particles as HIV‐1 vaccines , 2005, Reviews in medical virology.

[41]  Zhong Huang,et al.  Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. , 2006, Vaccine.

[42]  C. Proby,et al.  Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. , 2005, The Journal of investigative dermatology.

[43]  Rainer Fischer,et al.  Plant-based production of biopharmaceuticals. , 2004, Current opinion in plant biology.

[44]  J. M. Seguí-Simarro,et al.  Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. , 2008, Plant biotechnology journal.

[45]  C. Arntzen,et al.  Oral immunization with hepatitis B surface antigen expressed in transgenic plants , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Rose,et al.  Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato , 2003, Journal of Virology.

[47]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Baker,et al.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. , 1991, Biophysical journal.

[49]  N. Ravin,et al.  The use of transient expression systems for the rapid production of virus-like particles in plants. , 2013, Current pharmaceutical design.

[50]  R. Fischer,et al.  Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. , 2007, The Journal of general virology.

[51]  S. Landolfo,et al.  A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions , 2011, Archives of Virology.

[52]  H. Hausen,et al.  Characterization of a human papillomavirus from epidermodysplasia verruciformis lesions of a patient from upper‐volta , 1981, International journal of cancer.

[53]  L. Willmitzer,et al.  Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants , 2003, Journal of Virology.

[54]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .